Maria Panico
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Maria Panico has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
Anne Dell
Department of Life Sciences, Imperial College London, London, SW7 2AZ, UK
2 shared publications- Stuart M. Haslam
Department of Life Sciences, Imperial College London
2 shared publications - Angela Ballesteros
Section on Sensory Physiology and Biophysics, National Institute on Deafness and Other Communication Disorders
1 shared publication - Aristotelis Antonopoulos
Department of Life Sciences, Imperial College London, London SW7 2AZ, UK
1 shared publication - Charles J. Dimitroff
Department of Cellular and Molecular Medicine, Herbert Wertheim College of Medicine, Florida International University, Miami, FL 33199, USA
1 shared publication - Chiguang Feng
Department of Microbiology and Immunology, Institute of Marine and Environmental Technology, University of Maryland School of Medicine, 655 W Baltimore St S, Baltimore, MD 21201, USA
1 shared publication
Latest Publications
- Open Access
- 3 September 2020
- Published by Oxford University Press (OUP) in Glycobiology
- Vol. 31 (3) , 181-187
Site-specific characterization of SARS-CoV-2 spike glycoprotein receptor-binding domain
The novel coronavirus SARS-CoV-2, the infective agent causing COVID-19, is having a global impact both in terms of human disease as well as socially and economically. Its heavily glycosylated spike glycoprotein is fundamental for the infection process, via its receptor-binding domains interaction with the glycoprotein angiotensin-converting enzyme 2 on human cell surfaces. We therefore utilized an integrated glycomic and glycoproteomic analytical strategy to characterize both N- and O- glycan site-specific glycosylation within the receptor-binding domain. We demonstrate the presence of complex-type N-glycans with unusual fucosylated LacdiNAc at both sites N331 and N343 and a single site of O-glycosylation on T323.
- 3 September 2020
- Published by Oxford University Press (OUP) in Glycobiology
- Vol. 31 (3) , 181-187
Open AccessSite-specific characterization of SARS-CoV-2 spike glycoprotein receptor-binding domain
The novel coronavirus SARS-CoV-2, the infective agent causing COVID-19, is having a global impact both in terms of human disease as well as socially and economically. Its heavily glycosylated spike glycoprotein is fundamental for the infection process, via its receptor-binding domains interaction with the glycoprotein angiotensin-converting enzyme 2 on human cell surfaces. We therefore utilized an integrated glycomic and glycoproteomic analytical strategy to characterize both N- and O- glycan site-specific glycosylation within the receptor-binding domain. We demonstrate the presence of complex-type N-glycans with unusual fucosylated LacdiNAc at both sites N331 and N343 and a single site of O-glycosylation on T323.
- Open Access
- 13 April 2020
- Published by Oxford University Press (OUP) in Glycobiology
- Vol. 30 (11) , 895-909
Glycan characterization of pregnancy-specific glycoprotein 1 and its identification as a novel Galectin-1 ligand
Pregnancy-specific beta 1 glycoprotein (PSG1) is secreted from trophoblast cells of the human placenta in increasing concentrations as pregnancy progresses, becoming one of the most abundant proteins in maternal serum in the third trimester. PSG1 has seven potential N-linked glycosylation sites across its four domains. We carried out glycomic and glycoproteomic studies to characterize the glycan composition of PSG1 purified from serum of pregnant women and identified the presence of complex N-glycans containing poly LacNAc epitopes with α2,3 sialyation at four sites. Using different techniques, we explored whether PSG1 can bind to galectin-1 (Gal-1) as these two proteins were previously shown to participate in processes required for a successful pregnancy. We confirmed that PSG1 binds to Gal-1 in a carbohydrate-dependent manner with an affinity of the interaction of 0.13 μM. In addition, we determined that out of the three N-glycosylation-carrying domains, only the N and A2 domains of recombinant PSG1 interact with Gal-1. Lastly, we observed that the interaction between PSG1 and Gal-1 protects this lectin from oxidative inactivation and that PSG1 competes the ability of Gal-1 to bind to some but not all of its glycoprotein ligands.
- 13 April 2020
- Published by Oxford University Press (OUP) in Glycobiology
- Vol. 30 (11) , 895-909
Open AccessGlycan characterization of pregnancy-specific glycoprotein 1 and its identification as a novel Galectin-1 ligand
Pregnancy-specific beta 1 glycoprotein (PSG1) is secreted from trophoblast cells of the human placenta in increasing concentrations as pregnancy progresses, becoming one of the most abundant proteins in maternal serum in the third trimester. PSG1 has seven potential N-linked glycosylation sites across its four domains. We carried out glycomic and glycoproteomic studies to characterize the glycan composition of PSG1 purified from serum of pregnant women and identified the presence of complex N-glycans containing poly LacNAc epitopes with α2,3 sialyation at four sites. Using different techniques, we explored whether PSG1 can bind to galectin-1 (Gal-1) as these two proteins were previously shown to participate in processes required for a successful pregnancy. We confirmed that PSG1 binds to Gal-1 in a carbohydrate-dependent manner with an affinity of the interaction of 0.13 μM. In addition, we determined that out of the three N-glycosylation-carrying domains, only the N and A2 domains of recombinant PSG1 interact with Gal-1. Lastly, we observed that the interaction between PSG1 and Gal-1 protects this lectin from oxidative inactivation and that PSG1 competes the ability of Gal-1 to bind to some but not all of its glycoprotein ligands.